Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.46 |
| ▸ | LPL | P06858 | 5/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125910 | 0.91 | DGAT1 (0.57) | DGAT1LIPGLPLIRAK4PDGFRB | |
| SCHEMBL18015663 | 0.86 | DGAT1 (0.59) | DGAT1LIPGLPLIRAK4PDGFRB | |
| SCHEMBL15747744 | 0.85 | DGAT1 (0.52) | DGAT1LIPGLPLIDO1BCHE | |
| SCHEMBL29688361 | 0.84 | DGAT1 (0.70) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL30739 | 0.84 | DGAT1 (0.70) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL21390496 | 0.83 | DGAT1 (0.43) | DGAT1LIPGLPLKDM1AIDO1 | |
| SCHEMBL21290175 | 0.83 | DGAT1 (0.56) | DGAT1LIPGLPLKDM1ACYP3A4 | |
| SCHEMBL15747886 | 0.83 | DGAT1 (0.53) | DGAT1LIPGLPLIDO1PDGFRB | |
| SCHEMBL16787665 | 0.82 | DGAT1 (0.61) | DGAT1LIPGLPLKDM1APDGFRB | |
| SCHEMBL21125909 | 0.82 | DGAT1 (0.67) | DGAT1LIPGLPLPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| WO-2019179909-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | DGAT1 2190/4885LIPG 3983/4885LPL 3716/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | DGAT1 2190/4885LIPG 3983/4885LPL 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.